Preliminary data revealed that palmitoylation-deficient CD82 mutants (C5A/C74A/C83A) increased apoptotic susceptibility in breast cancer cells, although the mechanistic link between CD82 palmitoylation and drug sensitivity remains unexplored. This evidence concerns the gene CD82 and breast cancer.